NCT00129129 - Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine | Biotech Hunter

Enrollment

756

Participants

Timeline

Start Date

August 1, 2004

Primary Completion Date

September 15, 2005

Study Completion Date

March 29, 2006

Conditions

Haemophilus Influenzae Type bNeisseria Meningitidis

Interventions

BIOLOGICAL

GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine

Primary phase: 3 IM doses Booster phase: 1 IM dose

BIOLOGICAL

ActHIB

Primary phase: 3 IM doses Booster phase: 1 IM dose

BIOLOGICAL

Pediarix

Primary phase: 3 IM doses

BIOLOGICAL

Prevnar

Primary phase: 3 IM doses Booster phase: 1 IM dose

BIOLOGICAL

Menomune

Primary phase: 1 SC dose

Trial Locations (27)

10467

GSK Investigational Site, The Bronx

14620

GSK Investigational Site, Rochester

15010

GSK Investigational Site, Beaver Falls

15217

GSK Investigational Site, Pittsburgh

15227

GSK Investigational Site, Pittsburgh

15236

GSK Investigational Site, Pittsburgh

15241

GSK Investigational Site, Pittsburgh

16125

GSK Investigational Site, Greenville

16505

GSK Investigational Site, Erie

19046

GSK Investigational Site, Rydal

19401

GSK Investigational Site, Norristown

30062

GSK Investigational Site, Marietta

40004

GSK Investigational Site, Bardstown

40202

GSK Investigational Site, Louisville

40272

GSK Investigational Site, Louisville

44118

GSK Investigational Site, University Heights

44512

GSK Investigational Site, Boardman

50266

GSK Investigational Site, Des Moines

71111

GSK Investigational Site, Bossier City

72205

GSK Investigational Site, Little Rock

80112

GSK Investigational Site, Centennial

92708

GSK Investigational Site, Fountain Valley

06360

GSK Investigational Site, Norwich

02115

GSK Investigational Site, Boston

02118

GSK Investigational Site, Boston

02740

GSK Investigational Site, New Bedford

02886

GSK Investigational Site, Warwick